CClinicalTrials.gg
CompletedNCT04324541Updated May 17, 2024Results posted

Health & Aging Brain Study: Health Disparities TAU Project

An observational study in Brain Aging in Mexican Americans, sponsored by Sid E. O'Bryant. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Sid E. O'Bryant · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
50 Years and older
Sex
All
01

Study summary

By doing this study we are trying to learn more about brain aging in Mexican Americans.

Participants will be asked to complete a screening visit to determine if it is safe to undergo a PET scan.

If eligible, participants will undergo a medical procedure that takes a picture of their brain. This procedure is called a PET scan of the brain.

02

Conditions studied

  • Brain Aging in Mexican Americans
03

In context

Lead sponsor

This is the only study on the registry with Sid E. O'Bryant as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Mexican Americans that participated in the Health \& Aging Brain Study Amyloid Project

Inclusion criteria

  • Participation in the Health \& Aging Brain Study: Health Disparities Amyloid Project

Exclusion criteria

Exclusion Criteria:

  • Not a participant in the Health \& Aging Brain Study: Health Disparites Amyloid Project
  • Medical condition that precludes safe use of PET tracer
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (actual)
Patient registry
No

Groups and cohorts

  • Mexican American Adults

    No intervention

    Diagnostic Test: PET scan of the brain with Flortaucipir

Interventions

  • Diagnostic testPET scan of the brain with Flortaucipir

    PET scan of the brain with non FDA approved Radio tracer.

06

What researchers measure

Primary outcomes

  1. Tau Accumulation Measured by PET Imaging

    Tau PET scan completed and radiologist reviewed imaging and provided a report on whether or not Tau protein was present in the brain.

    Time frame: 4 weeks

07

Results

Posted May 17, 2024

Participant flow

Participant flow — Overall Study
MilestoneTau Scan Completed
Started12
Completed12
Not completed0

Outcome measures

PrimaryTau Accumulation Measured by PET Imaging

Tau PET scan completed and radiologist reviewed imaging and provided a report on whether or not Tau protein was present in the brain.

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Tau Accumulation Measured by PET Imaging
ParticipantsTau PET Scan Completed
Tau Accumulation Measured by PET Imaging12

Adverse events

Collected over 3 weeks, 3 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mexican American Adults0/16 (0%)0/16 (0%)0/16 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tau Scan Completed
<=18 years0
Between 18 and 65 years7
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)Tau Scan Completed
Female10
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tau Scan Completed
Hispanic or Latino12
Not Hispanic or Latino0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Tau Scan Completed
United States12
08

Study locations

1 site
  • University of North Texas Health Science Center Institute for Translational Research
    Fort Worth, Texas 76107, United States
09

References and documents

Study documents

  • Study protocol · Sep 13, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04324541
Lead sponsor
Sid E. O'Bryant
Responsible party
Sid E. O'Bryant (Executive Director, Institute for Translational Research Professor, Department of Pharmacology & Neuroscience, University of North Texas Health Science Center) — Sponsor-investigator
First posted
Mar 27, 2020
Start date
Sep 23, 2019
Primary completion
Oct 17, 2019
Completion
Apr 20, 2021
Results posted
May 17, 2024
Last update
May 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion